相关实验视频
Updated: Jul 2, 2025

08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
9.8K
人环素通过共享的基因表达反应特征签名诱导心脏毒性
E Renee Matthews1, Omar D Johnson2, Kandace J Horn3
1Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, United States of America.
PLoS genetics
|February 28, 2024
概括
在乳腺癌治疗中使用的拓糖酶II抑制剂 (TOP2i) 可以导致心脏损伤. 这项研究发现,TOP2i诱导心肌细胞的共同基因表达变化,影响的处理,并揭示了对这些心脏毒药物反应的个体遗传变异.
科学领域:
- 心脏病学 心脏病学
- 基因组学就是基因组学.
- 药理学 药理学 是一个学科.
背景情况:
- 拓酶II抑制剂 (TOP2i) 是重要的乳腺癌药物,但可以引起心脏毒性.
- 特定的TOP2i的心脏毒性作用,包括像多克索鲁比 (DOX) 这样的类环素 (AC),尚未完全理解.
- 个人对TOP2i的反应有所不同,这表明心脏毒性风险存在遗传因素.
研究的目的:
- 研究各种TOP2i对人类心肌细胞的心脏毒性作用.
- 为了识别由TOP2i引起的共享和独特的基因表达变化.
- 探索基因变异在对TOP2i心脏毒性的个人间反应中的作用.
主要方法:
- 从六名健康女性中诱导的多能干细胞衍生心肌细胞 (iPSC-CMs) 的治疗,使用DOX,Dunorubicin (DNR),Epirubicin (EPI),Mitoxantrone (MTX) 和Trastuzumab (TRZ).
- 评估细胞死亡,细胞应激和处理.
- 对全基因组基因表达变化的分析和响应特征的识别.
- 整合表达量的特征位点 (eQTL) 和全基因组/全转录组关联研究 (GWAS/TWAS) 数据.
主要成果:
- 所有测试的TOP2i都在临床相关度下诱导了细胞死亡,并在次致命剂量下影响了心肌细胞处理.
- TOP2i触发了成千上万的共享基因表达变化,分为早期急性,早期持续性和晚期反应特征,没有药物或AC特异性的模式.
- 与DOX反应和AC心脏毒性相关的单核酸多态性 (SNPs) 附近的基因被丰富在TOP2i反应基因中,表明对可变反应的遗传影响.
结论:
- TOP2i诱导心肌细胞中常见的分子反应,导致心脏毒性.
- 个体遗传变异影响对TOP2i的反应,解释心脏毒性的个体间差异.
- 了解这些共同的途径和遗传因素可以为个人化策略提供信息,以减轻癌症患者的TOP2i诱导的心脏损伤.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Electron Transport Chain: Complex I and II
13.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.3K
Induced Pluripotent Stem Cells
4.1K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.1K

